Additional therapy apart from plasmapheresis and steroids has been used for the management of TTP including rituximab which induces remission for more than 19 months [14] and caplacizumab which causes suppression of VWF for 48 hours and reduces overall relapse rates [15]. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.